Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zinc citrate + dipotassium glycyrrhizinate is a combination pharmaceutical product developed by the Third Affiliated Hospital of Southern Medical University for the treatment of oral inflammatory diseases, specifically gingivitis and periodontitis. Zinc citrate serves as an antimicrobial and anti-plaque agent; it releases zinc ions that inhibit bacterial metabolism, particularly glycolytic enzymes in oral pathogens like *Streptococcus mutans*, thereby reducing acid production and plaque accumulation. Dipotassium glycyrrhizinate, a salt derived from licorice root, provides potent anti-inflammatory and anti-allergic effects. It works by inhibiting the production of pro-inflammatory cytokines (such as TNF-alpha and IL-1beta) and may modulate the activity of 11-beta-hydroxysteroid dehydrogenase to enhance local anti-inflammatory responses. Together, the combination aims to control the bacterial load while simultaneously soothing inflamed gingival tissues.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zinc citrate + dipotassium glycyrrhizinate.